S
Sebastian Michels
Researcher at University of Cologne
Publications - 75
Citations - 3575
Sebastian Michels is an academic researcher from University of Cologne. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 18, co-authored 56 publications receiving 2548 citations. Previous affiliations of Sebastian Michels include University of Bonn.
Papers
More filters
Journal ArticleDOI
Comprehensive genomic profiles of small cell lung cancer
Julie George,Jing Shan Lim,Se Jin Jang,Yupeng Cun,Luka Ozretić,Gu Kong,Frauke Leenders,Xin Lu,Lynnette Fernandez-Cuesta,Graziella Bosco,Christian Müller,Ilona Dahmen,Nadine Jahchan,Kwon-Sik Park,Dian Yang,Anthony N. Karnezis,Dedeepya Vaka,Ángela Torres,Maia Segura Wang,Jan O. Korbel,Roopika Menon,Sung-Min Chun,Deokhoon Kim,Matthew D. Wilkerson,Neil Hayes,David Engelmann,Brigitte M. Pützer,Marc Bos,Sebastian Michels,Ignacija Vlasic,Danila Seidel,Berit Pinther,Philipp Schaub,Christian Becker,Janine Altmüller,Jun Yokota,Takashi Kohno,Reika Iwakawa,Koji Tsuta,Masayuki Noguchi,Thomas Muley,Hans Hoffmann,Philipp A. Schnabel,Iver Petersen,Yuan Chen,Alex Soltermann,Verena Tischler,Chang-Min Choi,Yong-Hee Kim,Pierre P. Massion,Yong Zou,Dragana Jovanovic,Milica Kontic,Gavin M. Wright,Prudence A. Russell,Benjamin Solomon,Ina Koch,Michael Lindner,Lucia Anna Muscarella,Annamaria la Torre,John K. Field,Marko Jakopović,Jelena Knezevic,Esmeralda Castaños-Vélez,Luca Roz,Ugo Pastorino,O.T. Brustugun,Marius Lund-Iversen,Erik Thunnissen,Jens Köhler,Martin Schuler,Johan Botling,Martin Sandelin,Montserrat Sanchez-Cespedes,Helga B. Salvesen,Viktor Achter,Ulrich Lang,Magdalena Bogus,Peter M. Schneider,Thomas Zander,Sascha Ansén,Michael Hallek,Jürgen Wolf,Martin Vingron,Yasushi Yatabe,William D. Travis,Peter Nürnberg,Christian Reinhardt,Sven Perner,Lukas C. Heukamp,Reinhard Büttner,Stefan A. Haas,Elisabeth Brambilla,Martin Peifer,Julien Sage,Roman K. Thomas +95 more
TL;DR: This first comprehensive study of somatic genome alterations in SCLC uncovers several key biological processes and identifies candidate therapeutic targets in this highly lethal form of cancer.
Journal ArticleDOI
Targeting RET in patients with RET-rearranged lung cancers: Results from the global, multicenter RET registry
Oliver Gautschi,Julie Milia,Thomas Filleron,Juergen Wolf,David P. Carbone,Dwight H. Owen,R. Camidge,Vignhesh Narayanan,Robert C. Doebele,Benjamin Besse,Jordi Remon-Masip,Pasi A. Jänne,Mark M. Awad,Nir Peled,Chul Cho Byoung,Daniel D. Karp,Michael Van Den Heuvel,Heather A. Wakelee,Joel W. Neal,Tony Mok,James Chih-Hsin Yang,Sai-Hong Ignatius Ou,Georg Pall,Patrizia Froesch,Gérard Zalcman,David R. Gandara,Jonathan W. Riess,Vamsidhar Velcheti,Kristin Zeidler,Joachim Diebold,Martin Früh,Sebastian Michels,Isabelle Monnet,Sanjay Popat,Rafael Rosell,Niki Karachaliou,Sacha I. Rothschild,Jin-Yuan Shih,Arne Warth,Thomas Muley,Florian Cabillic,Julien Mazieres,Alexander Drilon +42 more
TL;DR: The results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to the authors' knowledge, on outcomes of RET-directed therapy thus far, are presented.
Journal ArticleDOI
Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors
Sandra Ortiz-Cuaran,Matthias Scheffler,Dennis Plenker,llona Dahmen,Andreas H. Scheel,Lynnette Fernandez-Cuesta,Lydia Meder,Christine M. Lovly,Thorsten Persigehl,Sabine Merkelbach-Bruse,Marc Bos,Sebastian Michels,Rieke Fischer,Kerstin Albus,Katharina König,Hans-Ulrich Schildhaus,Jana Fassunke,Michaela Angelika Ihle,Helen Pasternack,Carina Heydt,Christian Becker,Janine Altmüller,Hongbin Ji,Christian Müller,Alexandra Florin,Johannes M. Heuckmann,Peter Nuernberg,Sascha Ansén,Lukas C. Heukamp,Johannes Berg,William Pao,Martin Peifer,Reinhard Buettner,Jürgen Wolf,Roman K. Thomas,Martin L. Sos +35 more
TL;DR: The data suggest that heterogeneous mechanisms of resistance can drive primary and acquired resistance to third-generation EGFR inhibitors and provide a rationale for potential combination strategies.
Journal ArticleDOI
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Matthias Scheffler,Michaela Angelika Ihle,Rebecca Hein,Sabine Merkelbach-Bruse,Andreas H. Scheel,Janna Siemanowski,Johannes Brägelmann,Anna Kron,Nima Abedpour,Frank Ueckeroth,Merle Schüller,Sophia Koleczko,Sebastian Michels,Jana Fassunke,Helen Pasternack,Carina Heydt,Monika Serke,Rieke Fischer,Wolfgang Schulte,Ulrich Gerigk,Lucia Nogova,Yon-Dschun Ko,Diana S.Y. Abdulla,Richard F. Riedel,Karl-Otto Kambartel,Joachim Lorenz,Imke Sauerland,Winfried Randerath,Britta Kaminsky,Lars Hagmeyer,Christian Grohé,Anna Eisert,Rieke Frank,Leonie Gogl,Carsten Schaepers,Alessandra Holzem,Martin Hellmich,Roman K. Thomas,Martin Peifer,Martin L. Sos,Reinhard Büttner,Jürgen Wolf +41 more
TL;DR: KRAS‐mutated NSCLC represents a genetically heterogeneous subgroup with a high frequency of co‐occurring mutations in cancer‐associated pathways, partly associated with distinct KRAS mutation subtypes.
Journal ArticleDOI
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Oliver Gautschi,Julie Milia,Bastien Cabarrou,Marie-Virginia Bluthgen,Benjamin Besse,Egbert F. Smit,Juergen Wolf,Solange Peters,Martin Früh,Dieter Koeberle,Youssouf Oulkhouir,Martin Schuler,Alessandra Curioni-Fontecedro,Benjamin Huret,Mallorie Kerjouan,Sebastian Michels,Georg Pall,Sacha I. Rothschild,Gerald Schmid-Bindert,Matthias Scheffler,Remi Veillon,Luciano Wannesson,Joachim Diebold,Gérard Zalcman,Thomas Filleron,Julien Mazieres +25 more
TL;DR: These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma and further trials are warranted to study combination therapies and drug resistance mechanisms.